Forging A New Understanding Of Iron In Neurodegenerative Disease.
Funder
National Health and Medical Research Council
Funding Amount
$598,573.00
Summary
Using the versatile model system, C. elegans, this proposal will define how normal functions of the brain become corrupted with age and hijacked by neurodegenerative diseases to cause dementia. Coupling specialised X-ray imaging only available at the Australian Synchrotron with the research excellence of the University of Melbourne, this Fellowship will provide a better understanding of normal ageing and how this relates to the development and progression of neurodegenerative diseases.
Regulation Of Cardiometabolic Disease By A Novel ATP Binding Cholesterol Transporter, ABCA8: A New Therapeutic Target?
Funder
National Health and Medical Research Council
Funding Amount
$316,585.00
Summary
Approximately 1.7 million Australians and 12% of the population in Singapore has type 2 diabetes (T2D). We have identified a cholesterol transporter, ABCA8, the absence of which produces symptoms similar to those seen in humans with T2D. The aim of this project is to understand the molecular basis of the diabetes symptoms in mice that do not have ABCA8 with a view to identifying this transporter as a drug target to reduce T2D and its complications, including heart attacks.
Determining The Clinical Effectiveness Of Antiviral Drugs Against Oseltamivir- And Laninamivir-resistant Influenza Viruses In Animal Models
Funder
National Health and Medical Research Council
Funding Amount
$388,067.00
Summary
Currently, the neuraminidase inhibitors are the only drugs that are effective against seasonal influenza viruses. However, viruses can develop resistance to these drugs. Using viruses with varied levels of resistance, the project will determine the effectiveness of different drug treatments in animal models. This will lead to better treatment for those patients seriously ill with drug-resistant influenza viruses.
Pericyte Dysfunction Limiting Energy Supply In Alzheimer's Disease
Funder
National Health and Medical Research Council
Funding Amount
$717,708.00
Summary
One possible cause of Alzheimer’s disease (AD) could be narrowing of small blood vessels (capillaries) within the brain, limiting blood flow and energy supply. Pericytes, a cell only on capillaries, maintain blood flow throughout the brain. I believe that pericytes may die in AD leading to an energy deficit and memory problems. I will test using human brains and animal models whether pericyte loss causes AD and how this is happening. Pericytes could provide a new therapy option for AD.
We need to think laterally to find effective treatments for people with dementia. Using relevant animal models and cutting-edge technology, my research investigates gene-environment interactions. In particular, my group is studying the pathophysiology of Huntington’s disease, a devastating progressive disorder with no current cure. By integrating my unique wide-ranging expertise and my extensive network of collaborators, I aim to explore mechanisms and to discover novel therapeutic strategies.
To understand how Hendra virus multiplies in infected cells, we will investigate the structure of its replicative machinery. This will provide the basis for rational drug design increasing Australia’s preparedness against the emergence of Hendra-like viruses.
Harnessing Lipid-reactive Immunity To Combat Mycobacterium Tuberculosis Infection
Funder
National Health and Medical Research Council
Funding Amount
$341,458.00
Summary
Critcial to the survival of Mycobacterium tuberculosis, the causative agent of tuberculosis (TB) is its unique waxy (lipid)-rich cell wall. This proposal aims to target components of its cell wall to devlop novel therapeutic strategies. Specifically, the Australian-Singapore alliance will examine how the immune system "sees" lipid based antigens from M. tuberculosis, and then will ultimately use this information towards the devlopment of novel lipid-based vaccines.
Alzheimer’s disease (AD), is the most common form of dementia, accounting for between 50-70% of all cases. There is general agreement that current treatments for AD/dementia are inadequate so new treatment strategies are desperately needed. I am addressing these challenges by developing new technologies to generate next generation treatments for AD.